거담제 시장 예측(-2034년) : 제품 유형, 제형, 약제 종류, 유통 채널, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Expectorant Drugs Market is accounted for $25.9 billion in 2026 and is expected to reach $78.7 billion by 2034 growing at a CAGR of 14.9% during the forecast period. Expectorant drugs are medications primarily used to facilitate the removal of mucus and secretions from the airways, particularly in the respiratory tract. These drugs work by thinning and loosening mucus in the lungs, making it easier to cough up and expel. They are commonly used to alleviate symptoms associated with respiratory conditions such as cough, congestion, and respiratory infections.

According to data released by the National Center for Biotechnology Information, cough accounted for about 8% of all consultations with primary care physicians worldwide.

Market Dynamics:

Driver:

Rising prevalence of respiratory conditions

With an increasing number of individuals affected by respiratory ailments like bronchitis, COPD, asthma, and respiratory infections, the demand for medications, particularly expectorant drugs, rises correspondingly. These medications play a pivotal role in managing the hallmark symptoms of these conditions, such as excessive mucus production, coughing, and chest congestion. As respiratory illnesses become more commonplace due to factors like air pollution, changing lifestyles, and infectious agents, the consistent need for expectorant drugs to alleviate symptoms and improve respiratory health drives market growth.

Restraint:

Increased side effects

The market for expectorant drugs is severely constrained by the growing number of adverse effects. As these medications aim to alleviate respiratory symptoms by thinning mucus, the rise in reported adverse effects like nausea, dizziness, or allergic reactions impacts patient tolerance and compliance. Heightened occurrences of side effects can deter patient adherence, leading to reduced confidence in these medications and potentially affecting market demand.

Opportunity:

Advancements in technology

Ongoing innovations drive the development of advanced drug formulations, improved delivery systems, and enhanced efficacy of expectorant medications. Novel technologies facilitate targeted drug delivery to affected respiratory areas, creating innovative formulations that optimise treatment outcomes and patient compliance. Additionally, advancements in personalised medicine and pharmacogenomics may lead to tailored expectorant therapies, ensuring more effective and personalised treatment approaches. Embracing these advancements addresses unmet medical needs, fostering growth and innovation in the expectorant drugs market.

Threat:

Regulatory hurdles

Complex regulatory frameworks, diverse regional requirements, and extended approval timelines create obstacles for introducing new expectorant medications. Overcoming these hurdles demands substantial investments in research and development, meticulous adherence to stringent regulatory guidelines, and effective collaboration with regulatory bodies. Failure to navigate these challenges can impede the timely introduction of innovative expectorant drugs, limiting market growth.

Covid-19 Impact

There was a surge in demand for expectorant drugs due to the emphasis on managing respiratory symptoms associated with COVID-19, such as cough and chest congestion. The pandemic prompted increased research into respiratory health, potentially leading to the development of new and improved expectorant drugs or formulations. Furthermore, during the initial pandemic phase, there may be a continuing need for expectorant medications due to the COVID-19's long-lasting effects on respiratory health and possible long-term respiratory problems.

The mucolytics segment is expected to be the largest during the forecast period

The mucolytics segment is estimated to hold the largest share. Mucolytics contain agents such as bromhexine, acetylcysteine, or ambroxol that work by disrupting the chemical bonds within mucus, making it less viscous and easier to expel through coughing. Mucolytics find application in various respiratory conditions like chronic bronchitis, COPD (chronic obstructive pulmonary disease), and cystic fibrosis, aiding in the clearance of excessive mucus and alleviating symptoms of congestion. Furthermore, their ability to target and modify the properties of mucus makes them a crucial component in managing respiratory disorders.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. Hospitals serve as major purchasers and distributors of expectorant drugs due to their role as primary centres for diagnosing and treating respiratory conditions. They procure a wide range of expectorant medications to manage patients with acute and chronic respiratory ailments, including pneumonia, bronchitis, and COPD exacerbations. In addition, hospitals maintain adequate stocks of these drugs to address the diverse respiratory health needs of patients admitted for respiratory care, emergency treatments, or chronic disease management, thereby significantly contributing to the demand within the expectorant drug market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising respiratory ailments, increasing pollution levels, and a larger population affected by seasonal infections. Furthermore, factors like urbanisation, changing lifestyles, and environmental pollutants contribute to respiratory issues, driving the demand for expectorant medications. Initiatives for affordable healthcare access and the presence of key market players investing in research and development contribute to the region's burgeoning expectorant drug market, catering to the diverse respiratory health needs of the Asia Pacific population.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to prevalent conditions like bronchitis, flu, and allergies. The region's robust healthcare infrastructure, advanced pharmaceutical research, and high awareness levels among the population about managing respiratory health issues foster market growth. Moreover, strategic initiatives for drug development, strong regulatory frameworks, and the presence of key market players focusing on innovation and product diversification further propel the North American expectorant drug market.

Key players in the market

Some of the key players in the Expectorant Drugs Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Beckman Coulter Inc., Mylan N.V., GSK plc, Glenmark Pharmaceuticals Limited, Johnson and Johnson, Novartis International AG, Merck KGaA, Pfizer inc, Sanofi SA, Vernalis plc, Proctor and Gamble Co, Dahur india Ltd, Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Aurobindo Pharma Ltd and Biocon.

Key Developments:

In October 2023, Efficient Laboratories, a Puerto Rican firm that distributes its brands of healthcare products, launched a new product, ROMPR PECHITO, an OTC medicine for children to relieve cold symptoms.

In September 2023, Genexa announced new clean over-the-counter (OTC) kids' medicines, further strengthening its leading role in bringing consumers clean, safe, and effective medications.

Products Covered:

• Prescription Drug
• Over the Counter (Otc)

Dosage Forms Covered:

• Oral Solid
• Oral Liquid
• Inhalant

Drug Types Covered:

• Secretion Enhancer
• Mucolytics
• Other Drug Types

Distribution Channels Covered:

• Drug Store
• Retail Store
• Online Pharmacies
• Other Distribution Channels

End Users Covered:

• Hospitals
• Speciality Centres
• Homecare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Expectorant Drugs Market, By Product

• 5.1 Introduction
• 5.2 Prescription Drug
• 5.3 Over The Counter (Otc)

6 Global Expectorant Drugs Market, By Dosage Form

• 6.1 Introduction
• 6.2 Oral Solid
• 6.7 Oral Liquid
• 6.8 Inhalant

7 Global Expectorant Drugs Market, By Drug Type

• 7.1 Introduction
• 7.2 Secretion Enhancer
  • 7.2.1 Potassium Citrate
  • 7.2.2 Sodium Citrate
  • 7.2.3 Ammonium Chloride
• 7.3 Mucolytics
  • 7.3.1 Bromhexine
  • 7.3.2 Ambroxol
  • 7.3.3 Carbocisteineurine
  • 7.3.4 Acetyl Cysteine
• 7.4 Other Drug Types

8 Global Expectorant Drugs Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Drug Store
• 8.3 Retail Store
• 8.4 Online Pharmacies
• 8.5 Other Distribution Channels

9 Global Expectorant Drugs Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Speciality Centres
• 9.4 Homecare
• 9.5 Other End Users

10 Global Expectorant Drugs Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Abbott Laboratories
• 12.2 Astrazeneca Plc.
• 12.3 Acella Pharmaceuticals LLC
• 12.4 Cipla Limited
• 12.5 Beckman Coulter Inc.
• 12.6 Mylan N.V.
• 12.7 GSK plc
• 12.8 Glenmark Pharmaceuticals Limited
• 12.9 Johnson and Johnson
• 12.10 Novartis International AG
• 12.11 Merck KGaA
• 12.12 Pfizer inc
• 12.13 Sanofi SA
• 12.14 Vernalis plc
• 12.15 Proctor and Gamble Co
• 12.16 Dahur india Ltd
• 12.17 Teva Pharmaceutical Industries Ltd.
• 12.18 Tris Pharma Inc.
• 12.19 Aurobindo Pharma Ltd
• 12.20 Biocon